ZLAB

SEC source: 0001567619-21-016385 · doc1.xml · nonDerivative · entry 3

Fu Tao · CIK 0001644888 · Director · President & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 211,094

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934

F3 · price: Reflects a weighted average sale price of $142.71 per share, at prices ranging from $142.21 to $143.18 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-016385 · doc1.xml · nonDerivative · entry 2

Fu Tao · CIK 0001644888 · Director · President & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 215,400

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934

F2 · price: Reflects a weighted average sale price of $141.92 per share, at prices ranging from $141.20 to $142.16 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-016385 · doc1.xml · nonDerivative · entry 1

Fu Tao · CIK 0001644888 · Director · President & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 217,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934

SEC source: 0001567619-21-016336 · doc1.xml · derivative · entry 6

Reinhart Harald · CIK 0001835824 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Ordinary Shares · 8,000 shares

Expires 2028-11-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires August 30, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F2 · derivative.exercise_date: The options vest in equal annual installments over five years beginning on 11/16/2019, the first anniversary of the date of grant.

SEC source: 0001567619-21-016336 · doc1.xml · nonDerivative · entry 4

Reinhart Harald · CIK 0001835824 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires August 30, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

SEC source: 0001567619-21-016336 · doc1.xml · nonDerivative · entry 3

Reinhart Harald · CIK 0001835824 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires August 30, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

SEC source: 0001567619-21-016336 · doc1.xml · derivative · entry 5

Reinhart Harald · CIK 0001835824 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,000

Underlying: Ordinary Shares · 8,000 shares

Expires 2028-11-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires August 30, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F2 · derivative.exercise_date: The options vest in equal annual installments over five years beginning on 11/16/2019, the first anniversary of the date of grant.

SEC source: 0001567619-21-016336 · doc1.xml · nonDerivative · entry 2

Reinhart Harald · CIK 0001835824 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires August 30, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

SEC source: 0001567619-21-016336 · doc1.xml · nonDerivative · entry 1

Reinhart Harald · CIK 0001835824 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires August 30, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

SEC source: 0001567619-21-021621 · doc1.xml · nonDerivative · entry 1

Edmondson Frazor Titus III · CIK 0001835780 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,069

F1 · kind: The shares were disposed of through a netting transaction to the issuer to cover taxes due. The reporting of this disposition to the issuer was delayed due to an administrative error.

SEC source: 0000899243-22-006147 · doc5.xml · nonDerivative · entry 3

DIEKMAN JOHN D · CIK 0001240357 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,019

SEC source: 0001567619-21-014550 · doc1.xml · nonDerivative · entry 1

DIEKMAN JOHN D · CIK 0001240357 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 61,852

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 31, 2021, may terminate on May 5, 2022 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

SEC source: 0001567619-21-014370 · doc1.xml · nonDerivative · entry 15

Du Ying · CIK 0001731790 · Director · Chairwoman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,008,653

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

SEC source: 0001567619-21-014370 · doc1.xml · nonDerivative · entry 14

Du Ying · CIK 0001731790 · Director · Chairwoman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,008,703

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F14 · price: Reflects a weighted average sale price of $147.64 per share, at prices ranging from $147.23 to $148.20 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-014370 · doc1.xml · nonDerivative · entry 13

Du Ying · CIK 0001731790 · Director · Chairwoman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,013,829

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F13 · price: Reflects a weighted average sale price of $146.68 per share, at prices ranging from $146.22 to $147.22 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-014370 · doc1.xml · nonDerivative · entry 12

Du Ying · CIK 0001731790 · Director · Chairwoman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,026,792

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F12 · price: Reflects a weighted average sale price of $145.75 per share, at prices ranging from $145.18 to $146.17 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-014370 · doc1.xml · nonDerivative · entry 11

Du Ying · CIK 0001731790 · Director · Chairwoman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,032,130

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F11 · price: Reflects a weighted average sale price of $144.71 per share, at prices ranging from $144.09 to $145.07 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-014370 · doc1.xml · nonDerivative · entry 10

Du Ying · CIK 0001731790 · Director · Chairwoman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,033,526

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F10 · price: Reflects a weighted average sale price of $143.39 per share, at prices ranging from $143.06 to $143.90 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-014370 · doc1.xml · nonDerivative · entry 9

Du Ying · CIK 0001731790 · Director · Chairwoman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,034,489

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F9 · price: Reflects a weighted average sale price of $141.78 per share, at prices ranging from $141.39 to $142.18 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-014370 · doc1.xml · derivative · entry 16

Du Ying · CIK 0001731790 · Director · Chairwoman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,000,276

Underlying: Ordinary Shares · 111,111 shares

Expires 2025-10-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F15 · derivative.exercise_date: The Stock Options fully vested as of October 22, 2020.

SEC source: 0001567619-21-014370 · doc1.xml · nonDerivative · entry 8

Du Ying · CIK 0001731790 · Director · Chairwoman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,116,649

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F8 · price: Reflects a weighted average sale price of $145.83 per share, at prices ranging from $145.73 to $146.03 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-014370 · doc1.xml · nonDerivative · entry 7

Du Ying · CIK 0001731790 · Director · Chairwoman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,034,870

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F7 · price: Reflects a weighted average sale price of $145.14 per share, at prices ranging from $144.70 to $145.69 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-014370 · doc1.xml · nonDerivative · entry 6

Du Ying · CIK 0001731790 · Director · Chairwoman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,037,942

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F6 · price: Reflects a weighted average sale price of $144.09 per share, at prices ranging from $143.69 to $144.69 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-014370 · doc1.xml · nonDerivative · entry 5

Du Ying · CIK 0001731790 · Director · Chairwoman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,098,347

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F5 · price: Reflects a weighted average sale price of $143.30 per share, at prices ranging from $142.66 to $143.65 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-014370 · doc1.xml · nonDerivative · entry 4

Du Ying · CIK 0001731790 · Director · Chairwoman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,108,530

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F4 · price: Reflects a weighted average sale price of $141.73 per share, at prices ranging from $141.33 to $142.30 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-014370 · doc1.xml · nonDerivative · entry 3

Du Ying · CIK 0001731790 · Director · Chairwoman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,112,573

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F3 · price: Reflects a weighted average sale price of $140.68 per share, at prices ranging from $140.29 to $141.29 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-014370 · doc1.xml · nonDerivative · entry 2

Du Ying · CIK 0001731790 · Director · Chairwoman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,114,598

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F2 · price: Reflects a weighted average sale price of $139.62 per share, at prices ranging from $139.19 to $140.18 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-014370 · doc1.xml · nonDerivative · entry 1

Du Ying · CIK 0001731790 · Director · Chairwoman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,116,649

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

SEC source: 0001567619-21-013659 · doc1.xml · derivative · entry 9

Fu Tao · CIK 0001644888 · Director · President & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 440,000

Underlying: Ordinary Shares · 10,000 shares

Expires 2028-07-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F7 · derivative.exercise_date: The Stock Options vest in equal annual installments over five years beginning on 09/24/2019, the first anniversary of the date of grant.

SEC source: 0001567619-21-013659 · doc1.xml · nonDerivative · entry 7

Fu Tao · CIK 0001644888 · Director · President & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 207,000

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F2 · price: Reflects a weighted average sale price of $170.30 per share, at prices ranging from $169.81 to $170.64 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-013659 · doc1.xml · nonDerivative · entry 6

Fu Tao · CIK 0001644888 · Director · President & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 207,100

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F5 · price: Reflects a weighted average sale price of $174.26 per share, at prices ranging from $173.94 to $174.80 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-013659 · doc1.xml · nonDerivative · entry 5

Fu Tao · CIK 0001644888 · Director · President & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 210,365

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F4 · price: Reflects a weighted average sale price of $173.56 per share, at prices ranging from $172.94 to $173.93 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-013659 · doc1.xml · nonDerivative · entry 4

Fu Tao · CIK 0001644888 · Director · President & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 213,646

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

SEC source: 0001567619-21-013659 · doc1.xml · nonDerivative · entry 3

Fu Tao · CIK 0001644888 · Director · President & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 213,667

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F3 · price: Reflects a weighted average sale price of $171.36 per share, at prices ranging from $170.89 to $171.88 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-013659 · doc1.xml · nonDerivative · entry 2

Fu Tao · CIK 0001644888 · Director · President & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 214,667

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F2 · price: Reflects a weighted average sale price of $170.30 per share, at prices ranging from $169.81 to $170.64 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-013659 · doc1.xml · nonDerivative · entry 1

Fu Tao · CIK 0001644888 · Director · President & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 217,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

SEC source: 0001567619-21-013527 · doc1.xml · derivative · entry 9

Reinhart Harald · CIK 0001835824 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,000

Underlying: Ordinary Shares · 4,000 shares

Expires 2028-11-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires August 30, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F3 · derivative.exercise_date: The options vest in equal annual installments over five years beginning on 11/16/2019, the first anniversary of the date of grant.

SEC source: 0001567619-21-013527 · doc1.xml · derivative · entry 8

Reinhart Harald · CIK 0001835824 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Ordinary Shares · 4,000 shares

Expires 2027-09-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires August 30, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F2 · derivative.exercise_date: The options vest in equal annual installments over five years beginning on 09/20/2018, the first anniversary of the date of grant.

SEC source: 0001567619-21-013527 · doc1.xml · nonDerivative · entry 6

Reinhart Harald · CIK 0001835824 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires August 30, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

SEC source: 0001567619-21-013527 · doc1.xml · nonDerivative · entry 5

Reinhart Harald · CIK 0001835824 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires August 30, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

SEC source: 0001567619-21-013527 · doc1.xml · nonDerivative · entry 4

Reinhart Harald · CIK 0001835824 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires August 30, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

SEC source: 0001567619-21-013527 · doc1.xml · nonDerivative · entry 3

Reinhart Harald · CIK 0001835824 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires August 30, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

SEC source: 0001567619-21-013527 · doc1.xml · derivative · entry 7

Reinhart Harald · CIK 0001835824 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,000

Underlying: Ordinary Shares · 8,000 shares

Expires 2027-09-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires August 30, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F2 · derivative.exercise_date: The options vest in equal annual installments over five years beginning on 09/20/2018, the first anniversary of the date of grant.

SEC source: 0001567619-21-013527 · doc1.xml · nonDerivative · entry 2

Reinhart Harald · CIK 0001835824 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires August 30, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

SEC source: 0001567619-21-013527 · doc1.xml · nonDerivative · entry 1

Reinhart Harald · CIK 0001835824 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires August 30, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

SEC source: 0001567619-21-012954 · doc1.xml · nonDerivative · entry 11

Du Ying · CIK 0001731790 · Director · Chairwoman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,008,653

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F11 · balance_after: Reflects a weighted average sale price of $177.84 per share, at prices ranging from $177.74 to $178.03 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-012954 · doc1.xml · nonDerivative · entry 10

Du Ying · CIK 0001731790 · Director · Chairwoman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,009,136

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F10 · balance_after: Reflects a weighted average sale price of $176.76 per share, at prices ranging from $176.40 to $177.17 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-012954 · doc1.xml · nonDerivative · entry 9

Du Ying · CIK 0001731790 · Director · Chairwoman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,009,663

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F9 · balance_after: Reflects a weighted average sale price of $175.55 per share, at prices ranging from $175.36 to $176.31 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-012954 · doc1.xml · nonDerivative · entry 8

Du Ying · CIK 0001731790 · Director · Chairwoman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,021,512

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F8 · balance_after: Reflects a weighted average sale price of $174.97 per share, at prices ranging from $174.36 to $175.35 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-012954 · doc1.xml · derivative · entry 12

Du Ying · CIK 0001731790 · Director · Chairwoman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,111,387

Underlying: Ordinary Shares · 111,111 shares

Expires 2025-10-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F12 · derivative.exercise_date: The Stock Options fully vested as of October 22, 2020.